VIRI has 36-month beta value of 1.64. Analysts have mixed views on the stock, with 0 analysts rating it as a “buy,” 0 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for VIRI is 23.36M, and currently, short sellers hold a 2.44% ratio of that float. The average trading volume of VIRI on June 27, 2024 was 1.07M shares.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
VIRI) stock’s latest price update
Virios Therapeutics Inc (NASDAQ: VIRI)’s stock price has plunge by -2.77relation to previous closing price of 0.24. Nevertheless, the company has seen a -10.77% plunge in its stock price over the last five trading sessions. globenewswire.com reported 2024-05-22 that ATLANTA, May 22, 2024 (GLOBE NEWSWIRE) — Virios Therapeutics, Inc. (Nasdaq: VIRI) (the “Company” or “Virios Therapeutics”), a development-stage biotechnology company focused on advancing novel antiviral therapies to treat debilitating chronic diseases, including fibromyalgia (“FM”) and Long-COVID (“LC”), today announced the closing of its previously announced public offering of 8,500,000 shares of its common stock at a public offering price of $0.20 per share. Gross proceeds from the offering are $1.7 million before deducting placement agent fees and offering expenses. Virios Therapeutics intends to use the net proceeds of the offering to commence preparatory activities for its planned IMC-2 Long-COVID Phase 2b study and for general corporate purposes.
VIRI’s Market Performance
Virios Therapeutics Inc (VIRI) has experienced a -10.77% fall in stock performance for the past week, with a -1.23% drop in the past month, and a -52.04% drop in the past quarter. The volatility ratio for the week is 15.41%, and the volatility levels for the past 30 days are at 18.97% for VIRI. The simple moving average for the last 20 days is -1.08% for VIRI stock, with a simple moving average of -56.06% for the last 200 days.
VIRI Trading at -27.26% from the 50-Day Moving Average
After a stumble in the market that brought VIRI to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -90.41% of loss for the given period.
Volatility was left at 18.97%, however, over the last 30 days, the volatility rate increased by 15.41%, as shares surge +4.09% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -49.31% lower at present.
During the last 5 trading sessions, VIRI fell by -11.88%, which changed the moving average for the period of 200-days by -75.89% in comparison to the 20-day moving average, which settled at $0.2350. In addition, Virios Therapeutics Inc saw -59.65% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at VIRI starting from Pridgen William, who purchase 15,335 shares at the price of $1.30 back on Aug 21 ’23. After this action, Pridgen William now owns 52,045 shares of Virios Therapeutics Inc, valued at $19,992 using the latest closing price.
Duncan Gregory Scott, the CHIEF EXECUTIVE OFFICER of Virios Therapeutics Inc, purchase 25,000 shares at $1.25 during a trade that took place back on Aug 17 ’23, which means that Duncan Gregory Scott is holding 57,461 shares at $31,245 based on the most recent closing price.
Stock Fundamentals for VIRI
The total capital return value is set at -1.96. Equity return is now at value -117.56, with -104.06 for asset returns.
Currently, EBITDA for the company is -5.45 million with net debt to EBITDA at 0.46. The liquidity ratio also appears to be rather interesting for investors as it stands at 5.66.
Conclusion
To put it simply, Virios Therapeutics Inc (VIRI) has had a bad performance in recent times. Analysts have a mixed opinion on the stock, with some rating it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
